Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Precigen Q1 2026 Earnings Call - PAPZIMEOS Revenue Surges 535% on Rapid Commercial Uptake
Precigen delivered a striking first quarter for its newly approved RRP therapy, PAPZIMEOS, with net product revenue jumping to $21.6 million from $3.4 million in the prior quarter. The acceleration re...
- PAPZIMEOS net product revenue surged 535% quarter-over-quarter to $21.6 million in Q1 2026, up from $3.4 million in Q4 2025.
- Total revenue reached $23.3 million, driven by strong commercial uptake of the newly approved RRP therapy.
- Operating loss improved to $6 million, with R&D expenses declining $4.8 million year-over-year as manufacturing costs are no longer expensed pre-approval.
- +11 more takeaways
MDxHealth Q1 2026 Earnings Call - Exiting Resolve UTI Business to Double Down on Prostate Cancer Diagnostics
MDxHealth is pulling the plug on its Resolve UTI test and closing its Plano, Texas lab to eliminate reimbursement uncertainty and refocus entirely on its prostate cancer precision diagnostics. The mov...
- MDxHealth is discontinuing its Resolve UTI test and closing its Plano, Texas laboratory to eliminate exposure to reimbursement uncertainty, particularly after Texas Medicare administrator Novitas Solutions reversed policy and sought $10.4 million in historical claim recoupments.
- Q1 2026 core prostate cancer revenue grew 11% year-over-year to $23.9 million on a pro forma basis, excluding the Resolve business entirely from the calculation.
- Pro forma gross margin for the quarter was 62.9%, down from 68% in Q1 2025, a decline management attributes to a shift in the mix between tissue-based and liquid-based testing.
- +7 more takeaways
Rapid Micro Biosystems Q1 2026 Earnings Call - Recurring Revenue Surges as Samsung Deal Drives Placements
Rapid Micro Biosystems delivered an 11% year-over-year revenue increase to $8 million in Q1 2026, fueled by a record 36% jump in product revenue and a 28% rise in recurring revenue, which now accounts...
- Total revenue grew 11% year-over-year to $8 million, driven by strong momentum in both system placements and recurring revenue streams.
- Product revenue surged 36% to $5.6 million, led by a record consumables quarter with over 30% growth as installed base utilization increased.
- Recurring revenue climbed 28% to $5.1 million, now representing 63% of total revenue and highlighting the shift toward a more predictable, service-heavy business model.
- +7 more takeaways
Inovio Pharmaceuticals Q1 2026 Earnings Call - FDA Review Proceeds Amidst Accelerated Approval Debate and Cash Runway Extended
Inovio Pharmaceuticals reported a streamlined first quarter with operating expenses down 13% as the company burns cash to advance its lead candidate, INO-3107, toward a PDUFA date of October 30, 2026....
- INO-3107 BLA review progresses with FDA completing mid-cycle review without raising new significant issues, setting stage for late-cycle review in Q3 2026.
- FDA has agreed to an informal meeting to discuss INO-3107's eligibility for accelerated approval, a critical regulatory hurdle for the October 30, 2026 PDUFA date.
- Inovio raised $16 million in an April 2026 public equity offering, strengthening its balance sheet and extending cash runway into Q1 2027.
- +7 more takeaways
Lightwave Logic Q1 2026 Earnings Call - Market Expansion and Silicon Photonics Integration
Lightwave Logic reported a 27% year-over-year revenue increase to approximately $29,000 for Q1 2026, while maintaining a strong cash position of $100 million after utilizing its existing shelf registr...
- Revenue for Q1 2026 reached approximately $29,000, marking a 27% year-over-year increase.
- Net loss for the quarter was $6.3 million, or $0.04 per share, compared to a net loss of $4.7 million in the prior year period.
- Cash on hand increased to approximately $100 million as of May 11, 2026, after utilizing existing shelf registrations.
- +12 more takeaways
Seer Q1 2026 Earnings Call - Revenue Misses Amid Academic Funding Slump, But Biobank Momentum and IP Defense Signal Long-Term Play
Seer reported a sharp Q1 2026 revenue decline to $2.8 million, driven by a prolonged slump in academic and government funding, lumpy service project timing, and increased competition from lower-priced...
- Q1 2026 total revenue fell 33% year-over-year to $2.8 million, missing expectations due to depressed academic funding, competitive pressure from inferior imitators, and a lumpy service pipeline that lacked a major Q1 project.
- Management reaffirmed full-year 2026 revenue guidance of $16 million to $18 million, projecting approximately 3% growth at the midpoint over 2025, citing a 9-to-12-month lag in consumable reorders from last year's strong instrument install base.
- Operating expenses were aggressively cut to $18.2 million, a $4.6 million year-over-year reduction, driven by lower employee compensation and professional services costs, demonstrating strict capital discipline despite the revenue headwinds.
- +7 more takeaways
Shoulder Innovations Q1 2026 Earnings Call - Revenue Surges 65% as New Product Launches and Commercial Execution Drive Upward Guidance
Shoulder Innovations delivered a blistering start to 2026 with first-quarter net revenue jumping 65% year-over-year to $16.7 million, fueled by aggressive commercial execution and successful new produ...
- Revenue accelerated to $16.7 million in Q1 2026, representing a 65% year-over-year increase and a 16% sequential jump, demonstrating strong momentum into the new fiscal year.
- Full-year 2026 revenue guidance was raised to $65–$68 million, reflecting 37–44% growth over 2025 and signaling management's high conviction in sustained commercial execution.
- Gross margins remained robust at 77.7%, up from 76.9% in the prior year, driven by improved average selling prices and the early benefits of cost-reduction initiatives.
- +7 more takeaways
ClearPoint Neuro Q1 2026 Earnings Call - 43% Revenue Growth Driven by IRRAS Acquisition and Record $12.1M Top Line
ClearPoint Neuro delivered a strong first quarter of 2026, reporting record revenue of $12.1 million, a 43% increase year-over-year. The growth was fueled by a 25% organic expansion in device sales an...
- Revenue surged 43% year-over-year to a record $12.1 million, driven by 25% organic device growth and the full contribution of the IRRAS acquisition.
- Gross margin expanded to 64%, up 4 percentage points from Q1 2025, primarily due to lower excess and obsolete inventory reserves.
- IRRAflow integration is proceeding smoothly, adding a dual-lumen catheter that extends brain access capabilities and addresses a portfolio gap.
- +7 more takeaways
Fluent Q1 2026 Earnings Call - Commerce Media Surges to 58% of Revenue as Company Transforms
Fluent is executing a decisive pivot from a legacy marketplace model to a high-growth Commerce Media platform. The company’s Commerce Media Solutions segment grew 104% year-over-year in Q1 2026, captu...
- Commerce Media Solutions revenue surged 104% year-over-year to $25.9 million, representing 58% of total consolidated revenue, up from just 23% a year prior.
- Total consolidated revenue fell 19% to $44.9 million, but this primarily reflects the divestiture of Call Solutions; continuing business revenue declined only 3% year-over-year.
- Gross profit in Commerce Media Solutions grew 78% year-over-year to $5.0 million, though management expects margins to return to the mid-20s as early-term incentives roll off throughout 2026.
- +7 more takeaways
GrabAGun Digital Holdings Q1 2026 Earnings Call - Margin Expansion and PEW Logistics Launch Signal a Structural Shift in Firearm Commerce
GrabAGun Digital Holdings delivered a quarter that defies the broader industry's stagnation. Revenue grew 11.1% to $25.9 million while adjusted NICS checks rose a mere 1.6%. Management attributes this...
- Revenue grew 11.1% year-over-year to $25.9 million, significantly outpacing the 1.6% rise in adjusted NICS background checks, signaling aggressive market share gains.
- Firearms product sales rose 10.5% to $21.7 million, driven by favorable product mix, AI-powered pricing, and expanded marketing capabilities.
- Gross margin expanded 107 basis points to 10.7% of net sales, reflecting a shift toward higher-margin firearms categories and improved pricing optimization.
- +7 more takeaways